drugset / Trial / NCT01214655
A Study for Patients With Acute Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukemia. Part A and Part B are dose escalation of two schedules in participants with acute leukemia. Parts A and B will enroll concurrently. Part C is a dose expansion for each schedule in participants with acute myeloblastic leukemia (AML).
Timeline
- Start
- 2008-06
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | litronesib | Small molecule | 2 mg/m2 | Intravenous |
| Subject | litronesib | Small molecule | 8 mg/m2 | Intravenous |